Monday, 18th September NSW State Cancer Conference 2023

1. Welcome from Session Chair
2. Welcome to Country
3. Conference Co-Chair Address
4. Opening Address

INVITED SPEAKERS: JIM CLEARY, NATALIE TAYLOR & ANTHONY GLOVER

• Palliative Care across the continuum of survivorship. - Jim Cleary
• From letting it happen to making it happen: realising the potential of cancer research through implementation science - Natalie Taylor
• Application of genomics to thyroid cancer management - Anthony Glover

INVITED SPEAKERS: CAMERON TURTLE & NIKOLA BOWDEN

• Factors governing outcomes of CD19 CAR-T cell immunotherapy for B cell malignancies - Cameron Turtle
• Drug repurposing to overcoming immunotherapy resistance - Nikola Bowden
• The Tolls to be paid: the detrimental impact of TLR4 rs11536889 on Helicobacter pylori-related stomach cancer - Ezekiel Otaegui-Campos
• Immunospatial tumour immune microenvironment (isTIME) organisation is associated with recurrence in primary melanoma - Grace H Attrill
• Deciphering the Crosstalk within the Tumor Microenvironment of NSCLC by a virtual microdissection approach - Sushant Parab
• Evaluating the safety and effect of chemotherapy and localised immunotherapy for the treatment of inoperable pancreatic cancer using an implantable device - Elahe Minaei
• Immune predictors of response to immunotherapy in metastatic cSCC - Benjamin Genenger
• HIGH-RISK HUMAN PAPILLOMAVIRUS DETECTION IN LYMPH NODE METASTASIS OF OESOPHAGEAL ADENOCARCINOMA; A WORLD-FIRST PILOT STUDY - Mohammad Rabiei

INVITED SPEAKERS: MEERA AGAR & JEANNE TIE

• Challenging the status quo: Why clinical trials in palliative care matter. - Meera Agar
• ctDNA and Localized Colon Cancer: Time for a Paradigm Change? - Jeanne Tie
• When, and how, should we talk about palliative care concepts with adolescents and young adults with cancer? Results from an international Delphi study - Ursula Sansom-Daly
• Quality of life and pain outcomes for cancer patients prescribed medicinal cannabis: the QUEST Initiative 12-month results - Margaret-Ann Tait
• International validation study of the Melanoma Institute Australia sentinel node metastasis risk nomogram. - Alexander H R Varey
• Impact of Chemotherapy-Induced Peripheral Neuropathy on Sleep Quality of Cancer Survivors  - Fawaz M Mahfouz
• Perceptions and interests of cannabis use among Oncology patients of Sydney, Australia. - Lara Eldering
• Novel Salivary miRNA Signatures for Early Diagnosis and Prediction of Oral Cancer - Jaikrishna Balakittnen

INVITED SPEAKERS: FLORIAN HONEYBALL & ABHIJIT PAL

• The Western NSW approach to managing inequity of access to cancer services - Florian Honeyball
• Practical solutions to improve equity, diversity and inclusion in NSW cancer clinical trials - Abhijit Pal
• Out-of-pocket healthcare costs for people with and without cancer in NSW - David E Goldsbury
• Understanding the impact of physical comorbidities on treatment commencement and completion, and quality of life, among older cancer patients in a rural Australian setting  - Alexandra Smith
• Identifying disparities in thyroid cancer staging at presentation across the rural-metropolitan continuum in Australia - Zihao M Yang
• Characterising patient safety events among people from culturally and linguistically diverse backgrounds accessing cancer care in New South Wales: A retrospective medical record review study. - Ashfaq Chauhan
• Are self-management resources feasible? Chinese-Australian immigrants’ experiences using a cancer self-management intervention (WeCope) - Verena S Wu
• Providing women aged 70-74 years with the rationale for cessation of breast cancer screening invitations: Results from a randomised trial - Rachael Dodd

• Drug targeting of colorectal cancers including cancer stem cells - REEM ALHULAIS
• Copper chelation downregulates YTHDF2 RNA-binding protein causing growth inhibition and decreased MYCN expression - Jessica L Bell
• Drugging the undruggable: targeting RNA-binding proteins as a therapeutic avenue against ovarian cancer - Jean Borges Bertoldo
• Targeting subcellular JNK activity in pancreatic cancer - Antonia L Cadell
• Characterisation of matched primary and metastatic cutaneous squamous cell carcinoma cell lines permit therapeutic testing in the immunosuppressed context  - Jessica Conley
• Targeting anti-androgen resistance in prostate cancer using physiologically relevant models - Michelle Devadason
• Telomere remodelling in drug resistant ER+ breast cancer - Leila Eshraghi
• Targeting autophagic initiation via both ULK1 and Beclin-1/VPS34 complexes increases chemotherapeutic potency in PDAC. - Josef Gillson
• Understanding metformin’s anti-cancer effect in prostate cancer using physiological preclinical models - Yi Fang Guan
• Loss of a growth arrest and DNA-damage inducible protein promotes resistance to a new form of cell death in leukaemia   - Nunki Hassan
• Knocking out dipeptidyl peptidase 9 gene expression in hepatocytes increases intrahepatic levels of activated caspase-1 protein in an experimental model of hepatocellular carcinoma. - JiaLi Huang
• SMG1 is a negative regulator of pro-oncogenic mTOR signalling independently of Nonsense Mediated Decay - Alexander C James
• Phytochemical drug combination approach to glioblastoma therapy  - Kasuni Kanapaddala Gamage
• Hiding in plain sight: tryptophan metabolism in hepatocellular carcinoma - Shivani Krishnamurthy
• Identification of drivers of resistance in BRAF^V600E paediatric high-grade glioma and novel therapeutic targets - Rebecca Lehmann
• Investigation of the presence of vasculogenic mimicry in matched primary and recurrent glioblastoma tissue - Kelsey Maddison
• Therapeutic value of targeting pro-nerve growth factor and its receptor sortilin in glioblastoma - Mark Marsland
• Uncovering the druggable RNA-binding proteome of childhood cancers for target-based drug discovery - John Paul Ong
• Developing representative models of ovarian cancer patient response to PARP inhibitors - Zoe Phan
• HPV16 and its impact on the RNA axis in head and neck cancers. - Dayna Sais
• Targeting Post-Translational Protein Modifications as a Novel Therapeutic Treatment Strategy in Diffuse Intrinsic Pontine Gliomas - Arjayeeta Samadder
• The Link Between Aberrations in the p53 Pathway and Outcomes from DNA-Damaging Therapies in Breast Cancer - Luiza Steffens Reinhardt
• Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq. - Michael Trpceski
• Effect of magnetic fields on glioblastoma cells: risk enhancement or potential adjuvant therapy?  - Millijoy Villanueva
• Inhibition of oxidative phosphorylation suppresses metabolically flexible glycolysis-competent cancer cell proliferation via replication stress independent of energy crisis - Xiao Hong Zhao
• Investigating novel matrisomal targets in PC to reduce fibrosis and improve standard-of-care chemotherapy. - Jessie Zhu
• Gut microbiome alteration is linked to changes in splenic T cell populations in colorectal cancer - Miguel Q Castaneda
• T-cell receptor therapies for the treatment of malignancies - Sayali Gore
• Features of immunotherapy response are prevalent in melanoma brain metastases compared to high grade gliomas - Bernadette Pedersen
• Targeting stromal cells to reverse immune suppression in triple negative breast cancer - Travis Ruan
• Non-invasive proteomic signatures for the diagnosis and classification of keratinocytic skin lesions   - Ali Azimi
• Scarless biopsy proteomics to discriminate between atopic dermatitis, psoriasis, and actinic keratosis - Lauren Faul
• Ultra-sensitive cancer rapid test of tumor immunotherapy biomarker - Jiayan Liao
• Development of a shortlist of tumour-specific methylated DNA regions with potential as a blood-based test for early ovarian cancer diagnosis - Kristina Warton
• Association between perioperative factors and DAH₃₀ in oncology patients undergoing hepatobiliary resection. - David T.Y. Chen
• Multiple Myeloma in the culturally and linguistically diverse Southwestern Sydney - A-M Joelle Marivel
• Ovarian cancer survival by racial and ethnic group: an analysis from the Ovarian Cancer Association Consortium - Nicola S Meagher
• Pharmaceutical opioid use and cancer incidence in the 45 and Up Study. - Peter Sarich
• Temporal change in etiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients with hepatocellular carcinoma in New South Wales, Australia - Yuen Kang Yeoh
• Flying a Nurse Practitioner 6-Month Pilot in Regional Outpatient Cancer Service - Kirsty Baxter
• Implementation of Geriatric Assessments in Cancer Care: An Umbrella Review - Sharon He
• Patient Access to Phase 1 Clinical Trials: the Scientia Experience - Charlotte Lemech
• Tailoring models of care to cancer centres during implementation of the Care to Quit Trial-a smoking cessation trial for patients affected with cancer - Christine Paul
• Patient navigation to improve cancer care among ethnic minority patients: A systematic review - Sandra Sonego
• Acceptability of an evidence-based booklet for HPV-related oropharyngeal squamous cell carcinoma patients and their partners - Rachael H Dodd
• Demographic and Clinical Factors Influencing Survival in Lung Cancer Patients: A Retrospective Rural Study - Alexandra Smith
• Patient reported outcome measures post radical cystectomy and urinary diversion for muscle invasive bladder cancer; the symptoms that matter most to patients - John JL Lahoud
• UNSW Biospecimen Services, incorporating the Health Precincts Biobank: Providing high quality biospecimens and data for translational research   - Ussha Pillai
• The effectiveness and cost-effectiveness of a digital health intervention to support breast cancer patients prepare for and recover from surgery: A randomised controlled trial protocol - Rebecca Wyse
• Transformer-guided multi-modal feature learning to standardise thorax radiotherapy structure nomenclature - Fahim Irfan Alam
• Computational modelling and simulations as tools for treatment personalisation in ovarian cancer - Marilisa Cortesi
• Data-driven dietetics dashboards in the digital era: Visualising real-world, evidence-based nutrition care and outcomes for patients with head and neck cancer - Merran Findlay
• Deep learning radiomics for survival prediction in non-small-cell lung cancer patients from CT images - Viet Huan Le
• Towards routine homologous recombination DNA repair deficiency testing for ovarian cancer patients - Nikilyn Nevins
• The Sensitivity and Specificity of Magnetic Resonance Imaging to Predict Seminal Vesicle Invasion in Prostate Cancer: A Systematic Review and Meta-Analysis - Jacob Bird
• Developing a bereaved-centred model of bereavement care for Nepean Blue Mountains Local Health District. - Luna Rodriguez Grieve
• Phase I/IIb dose-ranging study and development of a two-compartment model of vaporised cannabis flower bud in people with advanced cancer experiencing anorexia - Meera Agar
• Review of bereavement resources available at a NSW Local Health District. - Luna Rodriguez Grieve
• PROSPER:Proliferation Signature in Prognosticating ER+ Breast Cancer - Twingle Daniel
• Scrutinizing the whole genome for potential genes to design an African exclusive prostate cancer germline panel - Kazzem Gheybi
• Unravelling Immunotherapy Toxicity at Single Cell Resolution - Jennifer W Lim
• Revise, refine, reiterate: insights from beta testing an online paediatric oncology medicines database (ProCure) in preparation for implementation - Elijah Tyedmers
• Quantitative proteomics analysis identified plasma extracellular vesicles and particles derived protein markers related to prostate cancer. - Qi Wang
• A qualitative exploration of fear of cancer recurrence in caregivers - Hannah Banks
• Development of a brief screening tool for brain tumour caregivers' unmet needs - Jill Chen
• How do cancer survivors respond to receiving non-actionable germline genomic sequencing results? A qualitative insight.  - Clara Goossens
• Program factors influencing psychosocial outcomes in lung cancer screening: a systematic review - Kathleen McFadden
• A longitudinal study of lung cancer stigma in newly diagnosed patients - Shiho Rose
• Is conquer fear suitable for ovarian cancer survivors? - Kyra Webb
• Cancer Patient Population Projections in Australia: projections of colorectal cancer (2023-2027) - Katherine Barron
• Preoperative exercise and education for patients undergoing major abdominal cancer surgery. - Ruby Cole
• Impact of the COVID-19 pandemic on breast cancer screening and diagnosis: A systematic review  - Tong Li
• Mammographic density measurement tools: how well do they identify population breast screeners according to breast cancer risk? - Chelsea Carle
• Optimising Early Detection and Management of Lung Cancer: Empowering Pharmacists to Lead Lung Health Evaluation and Prioritisation - Simmie Chung
• Co-designing with General Practice to support National Bowel Cancer Screening Program participation - Stephanie SW Walker
• Clinical Characteristics and Surveillance Patterns in Patients with Hepatocellular Carcinoma in Australia: A 45 and Up Study - Emily He
• Mutational characteristics and immune infiltrates in early colorectal polyps - Jun Li
• A review of skin cancer primary prevention activities in primary care settings - Nehal Singh
• Preventing fatty liver-related liver cancers in Australia - Joachim Worthington
• Retrospective analysis of risk factors associated with cardiac hospital admissions in cancer patients treated with immune checkpoint inhibitors - Joshua Bennetts
• Overexpression of mitochondrial catalase in adipose tissue improves survival and cardiac cachexia in AOM-DSS model of colitis-associated colorectal cancer. - Amanda Croft
• Chronic pain in ambulatory patients attending a teaching hospital cancer centre. - Paul Glare
• Adverse Event Rates for Patients with Extensive Stage Small Cell Lung Cancer Treated at an Australian Tertiary Cancer Centre - Martin Hong
• SUPPORTIVE CARE NEEDS OF MEN DIAGNOSED WITH PROSTATE CANCER AND THEIR CLOSE ALLIES ACROSS PRIMARY TREATMENT MODALITIES (THE PCAN STUDY): A CROSS-SECTIONAL NATIONAL REGISTRY-BASED STUDY - Elizabeth Kennedy
• Investigating Clinical Profiles Associated with Recovery of Chemotherapy-Induced Peripheral Neuropathy - Tiffany Li
• Cross-cultural adaptation of the Breast Cancer and Lymphedema Symptom Experience Index (BCLE-SEI) in Marathi. - Vincent Singh Paramanandam
• What do doctors and nurses in cancer centres tell their patients about the benefits of quitting smoking after cancer? - Christine Paul
• Exploring the barriers to optimal survivorship care for people living with cancer in NSW - Helen Tran
• The costs of survivorship care for paediatric brain cancer survivors. - Chloe Willemsen
• Repurposing teniposide to target TGF-β in chemoresistant high-grade serous ovarian cancer - Michelle WY Brown
• Can we measure what matters? Feasibility of clinically prioritised colorectal cancer quality indicators with a New South Wales population-based linked dataset - Candice Donnelly
• Changes in numbers of circulating tumour cells as a biomarker for treatment response - Joachim Fluhrer
• Combined treatment with alpelisib and gefitinib exhibits strong synergy in a metastatic gastroesophageal cancer in vitro model  - Jacqueline Holliday
• How are surgeons trained in endocrine surgery? A mixed method study exploring competency in endocrine surgery in Australia and New Zealand - Tony Lian
• A systematic review of dentists’ knowledge, perception, practice and confidence in managing patients with cancers. - Sheau Ling Low
• Drug repurposing screen targeting PARP in high grade serous ovarian cancer - Bayley Matthews
• Development of 3D preclinical TNBC tumour models and investigation of novel anticancer targeted therapies - Farhana Mollah
• Toxicity on early phase cancer clinical trials: a single institution experience in South-West Sydney - Udit Nindra
• SPEAR: A Phase 2, Open-label, Single-arm Monotherapy Trial of Sulfasalazine in Pancreatic Adenocarcinoma – Trial in Progress  - Omali Pitiyarachchi
• Immune Checkpoint Inhibitor of Choice in Previously Treated Advanced Non-Small Cell Lung Cancer– A Systematic Review - Ahmed Rashed
• Personalised liver stereotactic body radiation therapy using magnetic resonance imaging: The PRISM clinical trial - Sirisha Tadimalla
• Exercise physiology in cancer care - Dylan West
• Achieving Enduring Work Participation for Cancer Survivors: A Person-Centred Approach   - Sue Woodall

INVITED SPEAKERS: A/PROF EMILY STONE & PROF PRADEEP TANWAR

• Lung cancer screening in Australia – sooner than you think? - Emily Stone
• Patient-derived organoids and their applications in clinical decision making - Pradeep Tanwar

3:20PM - 4:00PM: Panel Discussion: Barriers to effective screening 

A/Professor Emily Stone – St Vincent’s Hospital

Dr Mandy Ballinger – Garvan Institute for Medical Research 

Professor Pradeep Tanwar – University of Newcastle

A/Professor Kate McBride – Western Sydney University

Dr Usha Salagame – Pink Sari

Led by Aunty Yvonne Hill, Uncle Allan Hall, Uncle Cecil See

Workshop co-chairs Dr Merran Findlay, Dr David Mizrahi, and Dr Joanna Fardell

Presentations:

Nutrition Care of People with Head and Neck Cancer – Merran Findlay, UNSW Sydney, Sydney Local Health District and Chris O’Brien Lifehouse
Nurse-led survivorship care – Jordana McLoone, UNSW Sydney
Precision Medicine in paediatric oncology -David Ziegler, Children’s Cancer Institute

Panel chaired by A/Professor Natalie Taylor – UNSW Sydney

Workshop Co-chairs: Dr Georgina Kennedy, A/Professor James Wilmott, and A/Professor Tara Roberts

Workshop presented by:

Dr Tiberio Caetano – Chief Scientist, Gradient Institute

Panel:
A/Professor Winston Liauw, South Eastern Sydney Local Health District
A/Professor Fatemeh Vafaee, UNSW Sydney
Sheena Lawrance, Cancer Institute NSW

Presented by The Gradient Institute.